Sara Garcia-Rates | Neuroscience | Research Excellence Award

Published on by Awards and Recognitions

Research Excellence Award

Sara Garcia-Rates
Neuro Bio Ltd, United Kingdom
Sara Garcia-Rates
Affiliation Neuro Bio Ltd
Country United Kingdom
Scopus ID 23388862700
Documents 26
Citations 336
h-index 11
Subject Area Neuroscience
Event Research Awards and Recognitions
ORCID 0000-0002-1848-4811

Sara Garcia-Rates is a neuroscience researcher and biotechnology executive associated with Neuro Bio Ltd. With more than two decades of experience, her work focuses on neuroscience, neurodegenerative diseases, translational medicine, and biotechnology innovation. She has contributed to Alzheimer’s disease research through leadership in preclinical drug development, assay validation, intellectual property strategy, and scientific collaboration. Her academic background in pharmacology and biomedicine supports her role in advancing therapeutic development and translational research. Garcia-Rates combines scientific leadership with commercialization strategy, contributing to biomedical innovation and the development of novel approaches for neurodegenerative disease treatment.[1]

Abstract

Sara Garcia-Rates is a multidisciplinary neuroscience researcher specializing in neurodegenerative disease therapeutics, Alzheimer’s disease drug discovery, and translational biotechnology. Her work includes developing preclinical research strategies, expanding biotechnology patent portfolios, and advancing therapeutic candidates through international scientific collaborations. She has also contributed to neuropharmacology research focused on nicotinic receptor biology, neurotoxicity mechanisms, and receptor-mediated signaling pathways, establishing a strong profile in neuroscience innovation and therapeutic development.[2]

Keywords

Neuroscience, Alzheimer’s disease, neuropharmacology, biotechnology, translational medicine, preclinical development, nicotinic receptors, neurodegeneration, therapeutics, pharmacology, biotechnology leadership, drug discovery, intellectual property, neuroscience innovation.

Introduction

Sara Garcia-Rates has built an interdisciplinary research profile combining neuroscience, biotechnology, and translational medicine. Her work focuses on neurodegenerative diseases, neuronal signaling, receptor modulation, and therapeutic development, alongside contributions to biotechnology management, patent development, research funding, and scientific collaborations.[3]

Sara Garcia-Rates received advanced training in biology, pharmacology, and biomedicine at the University of Barcelona and completed postdoctoral research at the University of Oxford Department of Pharmacology. Her career combines academic neuroscience research with biotechnology leadership, focusing on translational biomedical science and therapeutic innovation.[2]

Research Profile

Sara Garcia-Rates serves as Chief Scientific Officer at Neuro Bio Ltd, where she has contributed since 2013. Her work includes leading preclinical neuroscience research, therapeutic development, experimental assay design, and intellectual property strategy. [1]

Her leadership includes overseeing scientific projects, managing multidisciplinary teams, and coordinating collaborative partnerships. Under her direction, the organization expanded its patent portfolio from two patents to twenty-two patent families related to neurodegeneration, oncology, anti-aging research, and therapeutic technologies.[4]

Sara Garcia-Rates has also contributed to funding acquisition strategies, scientific advisory board activities, and partnerships with universities, contract research organizations, and industrial collaborators. These activities illustrate the integration of scientific research with translational commercialization and innovation management within the biotechnology sector.[5]

Research Contributions

Garcia-Rates has contributed to neuroscience research on nicotinic receptors, neurotoxicity, intracellular signaling, and the effects of methamphetamine and MDMA exposure. Her studies focus on receptor-mediated pathways, oxidative stress, and neurochemical regulation in experimental systems.[2]

Her translational research includes developing therapeutic candidates for Alzheimer’s disease at Neuro Bio Ltd. She contributed to the evaluation and optimization of nearly two hundred compounds, supporting the development of preclinical therapies and patent-protected technologies for neurodegenerative disorders.[4]

Additional contributions include establishment of research partnerships across the United Kingdom and international biotechnology networks. Her work in collaborative development has supported external scientific collaborations, intellectual property growth, and strategic development of biotechnology assets involving therapeutic and diagnostic innovation.[5]

  • Leadership of Alzheimer’s disease therapeutic development programs.
  • Expansion of biotechnology patent portfolios and translational research assets.
  • Research on nicotinic receptor pharmacology and neurotoxicity.
  • Coordination of interdisciplinary scientific collaborations and advisory activities.
  • Management of preclinical neuroscience development programs.

Publications

Sara Garcia-Rates has published research in neuropharmacology, receptor biology, and neuroscience, focusing on neurotoxicity, nicotinic receptor regulation, intracellular signaling, and neurochemical mechanisms. Her work contributes to the understanding of receptor-mediated neurological disorders and includes both scientific journal articles and book chapters on methamphetamine- and MDMA-related neurotoxicity.[2]

  1. Garcia-Ratés S, Camarasa J, Escubedo E, Pubill D. Methamphetamine and 3,4-methylenedioxymethamphetamine interact with central nicotinic receptors and induce their upregulation. Toxicology and Applied Pharmacology, 2007.
  2. Chipana C, García-Ratés S, Camarasa J, Pubill D, Escubedo E. Different oxidative profile and nicotinic receptor interaction of amphetamine and MDMA. Neurochemistry International, 2008.
  3. Garcia-Ratés S, Camarasa J, Sánchez-García AI, Gandía L, Escubedo E, Pubill D. Effects of MDMA on nicotinic receptors and intracellular calcium increase. Toxicology and Applied Pharmacology, 2010.
  4. Pubill D, Garcia-Ratés S, Camarasa J, Escubedo E. Neuronal nicotinic receptors as new targets for amphetamine derivatives. Pharmaceuticals, 2011.

Research Impact

The research activities of Sara Garcia-Rates demonstrate impact across both academic neuroscience and biotechnology innovation. Her publication metrics include twenty-six indexed documents, more than three hundred citations, and an h-index of eleven, reflecting measurable scholarly engagement within the neuroscience research community.[1]

Garcia-Rates has contributed to biotechnology development through preclinical therapeutic research, patent expansion, and translational neuroscience projects focused on neurodegenerative diseases. She has also supported commercialization efforts, investment acquisition, and research funding to advance biotechnology innovation and organizational growth.[4]

Her scientific leadership has also included mentoring activities, partnership development with academic institutions, and participation in scientific advisory initiatives. These contributions indicate broader influence beyond publication metrics alone, extending into organizational development and interdisciplinary scientific collaboration.[5]

Award Suitability

Sara Garcia-Rates combines expertise in neuroscience research, translational biomedical science, and biotechnology leadership. Her work in therapeutic development, scientific publications, intellectual property expansion, and collaborative research reflects sustained contributions to neuroscience and biotechnology innovation.[3]

Her ability to lead multidisciplinary scientific projects and contribute to translational therapeutic development highlights her role in modern biomedical research. Her work in therapeutic innovation, patent expansion, and scientific collaboration demonstrates continued engagement in neuroscience research and biotechnology advancement.[4]

Conclusion

Sara Garcia-Rates has built a multidisciplinary career in neuroscience research, biotechnology leadership, and therapeutic development. Through her work at Neuro Bio Ltd and her scientific publications, she has contributed to neuropharmacology research, Alzheimer’s disease therapeutics, and biotechnology innovation.[5]

References

  1. Elsevier. (n.d.). Scopus author details: Sara Garcia-Rates, Author ID 23388862700. Scopus. https://www.scopus.com/authid/detail.uri?authorId=23388862700
  2. Garcia-Ratés S, Camarasa J, Escubedo E, Pubill D. (2007). Methamphetamine and 3,4-methylenedioxymethamphetamine interact with central nicotinic receptors and induce their upregulation. Toxicology and Applied Pharmacology. https://doi.org/10.1016/j.taap.2007.05.019
  3. Pubill D, Garcia-Ratés S, Camarasa J, Escubedo E. (2011). Neuronal nicotinic receptors as new targets for amphetamine derivatives. Pharmaceuticals. https://doi.org/10.3390/ph4060822
  4. Neuro Bio Ltd. (2025). Research development activities, patent portfolio expansion, and preclinical neuroscience initiatives. 
  5. Awards and Recognitions. (n.d.). Research Awards and Recognitions official website. https://awardsandrecognitions.com/

Dr. Tigran Petrosyan | Neuroscience | Best Researcher Award

Published on by Awards and Recognitions

Dr. Tigran Petrosyan | Neuroscience | Best Researcher Award

Dr. Tigran Petrosyan | Neuroscience – Associate professor at Yerevan Haybusak University, Armenia

Dr. Tigran Petrosyan is a distinguished researcher in the fields of health sciences and neuroscience, known for his impactful contributions to the study of neuroprotection, neuroregeneration, and motor function recovery. His research has particularly focused on the therapeutic potential of bacterial melanin in treating central nervous system (CNS) injuries and neurodegenerative disorders such as Parkinson’s disease. With over 600 citations, a strong h-index of 17, and a research portfolio spanning over a decade, Dr. Petrosyan stands as a committed and innovative scientist in experimental neurobiology.

Profile Verified:

Google Scholar

Education:

Dr. Petrosyan’s academic journey is rooted in a rigorous scientific education in biomedical and health sciences, with specialization in neuroscience and motor system rehabilitation. His graduate and postgraduate training emphasized neurophysiology, neuroimmunology, and experimental therapeutics, equipping him with the theoretical knowledge and methodological tools to conduct high-level laboratory research. His deep academic foundation supports his ability to design and lead investigations involving CNS injury models, behavioral assessments, and neurochemical analysis.

Experience:

With extensive experience in experimental research, Dr. Petrosyan has worked in multiple neuroscience-focused research environments, contributing to both academic and applied studies. He has developed and led studies involving corticospinal tract lesions, substantia nigra degeneration, and sciatic nerve injuries in rodents. He has also collaborated on projects involving motion analysis systems, cognitive recovery, and rehabilitative therapies, often blending behavioral neuroscience with biomedical engineering tools. His portfolio includes peer-reviewed publications, research supervision, and inter-institutional collaborations.

Research Interest:

Dr. Petrosyan’s research interests lie in neuroprotective mechanisms, neuroregeneration, and the therapeutic applications of natural compounds, particularly bacterial melanin. His work has shown the compound’s ability to cross the blood-brain barrier, reduce inflammation, enhance neural activity, and support motor function recovery in animal models. He is also interested in movement disorders, sensorimotor rehabilitation, and alternative communication systems for individuals with disabilities, demonstrating his commitment to both scientific innovation and social impact.

Award:

Dr. Petrosyan’s scientific contributions, particularly in the study of bacterial melanin as a novel neuroprotective agent, have made a significant impact in the field of neuroscience. His research has been consistently cited and discussed in international literature, including journals on neurophysiology, motor behavior, and neuroimmune biology. These accomplishments make him a highly suitable candidate for the Best Researcher Award, recognizing both the depth and translational relevance of his work.

Publications:

🧠 “Neuroprotective action of bacterial melanin in rats after corticospinal tract lesions” – Pathophysiology, 2012, cited by 50 articles;
🏃 “Application of motion capture systems in ergonomic analysis” – Armenian Journal of Special Education, 2020, cited by 38 articles;
🧪 “Effects of bacterial melanin on motor recovery… in rats” – Neuropeptides, 2014, cited by 37 articles;
⚡ “Bacterial melanin increases electrical activity of neurons…” – Journal of Neural Transmission, 2014, cited by 30 articles;
🧬 “Bacterial melanin in rat models of Parkinson’s disease” – Neural Regeneration Research, 2015, cited by 26 articles;
🧍 “Initial training facilitates posttraumatic motor recovery…” – Somatosensory & Motor Research, 2015, cited by 26 articles;
🧫 “Bacterial melanin crosses the blood–brain barrier…” – Fluids and Barriers of the CNS, 2014, cited by 25 articles.

Conclusion:

In summary, Dr. Tigran Petrosyan exemplifies a strong blend of scientific rigor, innovation, and dedication to applied neuroscience. His research has contributed new perspectives to the treatment of CNS injuries and neurodegenerative diseases, particularly through the exploration of bacterial melanin as a therapeutic agent. With a solid publication record, strong citation metrics, and a broad research scope that spans from molecular neuroscience to rehabilitative technology, Dr. Petrosyan is an outstanding candidate for the Best Researcher Award, and his continued work promises further contributions to neuroscience and health sciences.